Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304329 | 1.00 | ABCB1 (0.52) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4851546 | 0.98 | ABCB1 (0.51) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL7351021 | 0.98 | ABCB1 (0.51) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 | |
| SCHEMBL589202 | 0.89 | SLC15A1 (0.61) | ALDH1A1SLC15A1MAPK1L3MBTL1SLC7A5 | |
| SCHEMBL32681189 | 0.89 | SLC15A1 (0.61) | ALDH1A1SLC15A1MAPK1L3MBTL1SLC7A5 | |
| SCHEMBL589203 | 0.89 | SLC15A1 (0.61) | ALDH1A1SLC15A1MAPK1L3MBTL1SLC7A5 | |
| SCHEMBL1264374 | 0.89 | SLC15A1 (0.61) | ALDH1A1SLC15A1MAPK1L3MBTL1SLC7A5 | |
| SCHEMBL8249778 | 0.88 | SLC15A1 (0.57) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 | |
| SCHEMBL30916032 | 0.88 | SLC15A1 (0.57) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 | |
| SCHEMBL7470329 | 0.88 | SLC15A1 (0.57) | ABCB1ALDH1A1SLC15A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499127-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2328865-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| CN-104447707-B | Hepatitis c virus inhibitors | 百时美施贵宝公司 | 2017-04-12 | — | — | CN | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-7323456-B2 | Carboxylic acid derivatives compounds and agents comprising the compounds as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-20040254370-A1 | Carboxylic acid derivatives compounds and agents comprising the compounds as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1445256-A1 | CARBOXYLIC ACID DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | ABCB1 244/4885ALDH1A1 1107/4885SLC15A1 3946/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20040254370-A1 | Carboxylic acid derivatives compounds and agents comprising the compounds as active ingredient | SREBF1, GPR119, PPARG | ABCB1 923/4885ALDH1A1 355/4885SLC15A1 804/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ABCB1 200/4885ALDH1A1 1144/4885SLC15A1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.